Acadia Pharmaceuticals
ACAD
182 hedge funds and large institutions have $3.06B invested in Acadia Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 53 increasing their positions, 68 reducing their positions, and 12 closing their positions.
460% more call options, than puts
Call options by funds: $195M | Put options by funds: $34.8M
192% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 12
31% more capital invested
Capital invested by funds: $2.33B → $3.06B (+$723M)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
12% more funds holding
Funds holding: 162 → 182 (+20)
22% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 68
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$24.5M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$18.4M |
| 3 |
JP Morgan Chase
New York
|
+$15.2M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$15M |
| 5 |
CCI
Columbus Circle Investors
|
+$12.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$38.8M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$13.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.3M |
| 4 |
Bank of New York Mellon
New York
|
-$8.23M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.58M |
ACAD Hedge Fund Activity: Q4 2014 in Review
182 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2014, worth a combined $3.06B — up 31% from $2.33B a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new ACAD positions and 12 closed out — a net gain of 23 holders — while 53 added to existing stakes and 68 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $24.5M. The largest seller was Viking Global Investors, cutting an estimated $38.8M.
- 182 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2014, up from 162 in Q3 2014.
- Funds reported $3.06B of Acadia Pharmaceuticals stock for Q4 2014, up 31% quarter-over-quarter.
- 35 funds opened new Acadia Pharmaceuticals positions in Q4 2014 and 12 closed out, a net change of +23 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2014 was Sabby Management, an estimated $24.5M added.
- The largest Acadia Pharmaceuticals seller in Q4 2014 was Viking Global Investors, an estimated $38.8M sold.
Based on aggregated 13F filings for Q4 2014.